Last reviewed · How we verify
PG101
At a glance
| Generic name | PG101 |
|---|---|
| Also known as | Topical gel, Topical gel suspension |
| Sponsor | Rhodes Pharmaceuticals, L.P. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study (PHASE2)
- Safety and Efficacy of PG101 for Dry Eye Syndrome (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PG101 CI brief — competitive landscape report
- PG101 updates RSS · CI watch RSS
- Rhodes Pharmaceuticals, L.P. portfolio CI